ERBB2 and gastric cancer: To date, better success in treating GC has been obtained using the monoclonal antibody trastuzumab and the antibody-drug conjugate trastuzumab deruxtecan (DS-8201) against human epidermal growth factor receptor 2 (HER2 receptor) [141,142], and the monoclonal antibody ramucirumab against vascular endothelial growth factor-2 (VEGFR-2) [143].